• E-mail page
• Print page
• Text size   

AstraZeneca is committed to helping your at-risk patients reach the goals you set for them. That’s why we have several ongoing programs to help patients lower the out-of-pocket costs of managing their cholesterol.

30-Day Free Trial Offer

At-risk patients who are considering CRESTOR may receive a 30-day free trial offer when they order a Take Action Kit. When you write a prescription, your patient can redeem his or her free trial certificate for a month’s supply of CRESTOR.

CRESTOR Savings Card

At-risk patients who sign up for the CRESTOR 360°™ Patient Support Program may be eligible for a CRESTOR Savings Card. With the Savings Card, qualified patients pay no more than $25 for their next 12 prescriptions for CRESTOR. (Subject to eligibility. Restrictions apply.) Patients can register for the CRESTOR 360° Program at CRESTOR.com.

AZ&Me™ Prescription Savings Program

If your patients take any of our medicines but cannot afford them, AstraZeneca may be able to help through one of the AZ&Me Prescription Savings Programs. Find out more about AZ&Me.

^†Defined as covered without prior authorization on commercial, Medicare Part D, and Medicaid formularies. Patients without prior authorization means covered lives at Tiers 1 to 7 calculated by Fingertip Formulary as of June 2009 that do not require additional information to the health plan in order for CRESTOR to be covered. Data include covered lives whose prescriptions may be subject to step-therapy requirements.¹

• CRESTOR is indicated^# as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

Important safety information about CRESTOR

• CRESTOR is contraindicated^# in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡